Seasonal Respiratory Syncytial Virus Prophylaxis Based on Predetermined Dates Versus Regional Surveillance Data

Paes, Bosco; Craig, Carole; Pigott, Wendy; Latchman, Andrew

doi:10.1097/inf.0b013e31829479d3

Cited by 16 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these cases, immune prophylaxis with monthly injections of palivizumab is recommended during the RSV season [ 7 ]. Early initiation of immune prophylaxis increases the costs, as more than five doses are necessary to protect a child for the whole season, while a late initiation leave them unprotected during the beginning of the season [ 8 ]. There are geographical variations at the start and end of the outbreak and understand them can help optimize immune prophylaxis strategies.…”

Section: Introductionmentioning

confidence: 99%

Respiratory syncytial virus hospitalization in children in northern Spain

et al. 2018

View full text Add to dashboard Cite

ObjectivesUnderstanding respiratory syncytial virus (RSV) morbidity may help to plan health care and future vaccine recommendations. We aim to describe the characteristics and temporal distribution of children diagnosed with RSV admitted in a Spanish hospital.MethodsDescriptive study for which the hospital discharges of children < 5 years of age with RSV infection were analyzed. The information was extracted from the hospital discharge database of a reference pediatric hospital in northern Spain for the 2010–2011 to 2014–2015 RSV seasons.ResultsSix hundred and forty-seven hospitalizations of children with RSV infection were analyzed, 94% of which occurred between the second week of November and the last week of March. Most children (72%) were under one year of age and 95% were previously healthy infants. Infants born from October to December had the highest risk of hospitalization in the first year of life. The median length of hospital stay of children with and without comorbidities was six and three days, respectively. 6.5% of the hospitalized cases were admitted to the pediatric intensive care unit; this percentage was higher among children < 2 months (adjusted odds ratio 4.15; 95% confidence interval: 1.37–12.61) or with comorbidities (adjusted odds ratio 4.15; 95% confidence interval: 1.53–11.28). The case lethality was 0.3%.ConclusionsThe risk of hospitalizations for RSV is high during the first year of life and increases among infants born in the fall. Being under two months of age and presenting comorbidities are the main risk factors associated to pediatric intensive care unit admission.

show abstract

Section: Introductionmentioning

confidence: 99%

Respiratory syncytial virus hospitalization in children in northern Spain

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The presumed start of the RSV season, and the start of prophylaxis with palivizumab, is often set by regional healthcare authorities based on historical data in those areas. A recent analysis of Canadian data found that the most effective method of determining the start of the RSV season was through the surveillance of virology data from local laboratories, assuming a 2-day turnaround in laboratory results [ 28 ]. In Ireland and the Netherlands, the RSV season usually extends from September/October through March/April and palivizumab prophylaxis typically begins in early October.…”

Section: Rsv Prophylaxis Overviewmentioning

confidence: 99%

Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands

Whelan

Musters

Murray³

et al. 2016

Drugs Ther Perspect

View full text Add to dashboard Cite

Severe infection of infants with respiratory syncytial virus (RSV) is a leading cause of morbidity in the developed world and mortality in the developing world. Prophylaxis using palivizumab in infants at risk for severe RSV disease reduces the rate of hospitalisation in this population of children. To ensure complete prophylaxis, infants must receive monthly doses over the winter season. To improve parental convenience, the Synacare® programme was implemented in Ireland and the Netherlands. Synacare® is now a longstanding programme in which palivizumab is administered in the home setting by skilled nurses. Protocols and procedures described here illustrate the efficiency and acceptability of the home delivery service of RSV disease prophylaxis. Post-administration surveys have indicated a high level of parental satisfaction with the programme. At-home paediatric programmes like Synacare® may serve as an alternative to burdensome monthly hospital visits and may lead to enhanced clinical outcomes.

show abstract

“…Besides therapeutic treatment, another possible strategy in high‐risk COPD patients is prophylaxis in a household or community setting. Most acute respiratory infections, including influenza and RSV, cause seasonal epidemics during 2–4 months, and seasonal prophylaxis would be an option to prevent such infections . Drug compliance during seasonal prophylaxis may not be easily achieved in some patients, and the rather low degree of seasonality of rhinovirus infection together with the possibility of resistance development toward the drugs with a low barrier to resistance (such as capsid binders) disfavors prophylactic use.…”

Section: Which Patients Would Benefit From Anti‐rhinovirus Therapy Anmentioning

confidence: 99%

Toward antiviral therapy/prophylaxis for rhinovirus‐induced exacerbations of chronic obstructive pulmonary disease: challenges, opportunities, and strategies

Thibaut

Lacroix

Palma

et al. 2015

Reviews in Medical Virology

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a life-threatening lung illness characterized by persistent and progressive airflow limitation. Exacerbations of COPD contribute to the severity of this pathology and accelerate disease progression. To date, pharmacological treatment of both stable COPD patients and patients experiencing exacerbations is mainly symptomatic with bronchodilators and steroids as the mainstay of therapy. Bacteria trigger such exacerbations in a number of cases; hence, antibiotics might be included in the treatment as well. Several respiratory viruses are frequently detected in sputum from patients during COPD exacerbations. These include influenza viruses, respiratory syncytial virus, and, most often, rhinoviruses. In this review, we discuss the potential use of an anti-rhinovirus drug for the treatment and prophylaxis of rhinovirus-induced COPD exacerbations and the path forward toward the development and use of such a drug.

show abstract

Seasonal Respiratory Syncytial Virus Prophylaxis Based on Predetermined Dates Versus Regional Surveillance Data

Cited by 16 publications

References 11 publications

Respiratory syncytial virus hospitalization in children in northern Spain

Respiratory syncytial virus hospitalization in children in northern Spain

Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands

Toward antiviral therapy/prophylaxis for rhinovirus‐induced exacerbations of chronic obstructive pulmonary disease: challenges, opportunities, and strategies

Contact Info

Product

Resources

About